The only federally approved CBD product in the U.S. has been OK’d by European authorities for use there.
The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday.
In June 2018, the U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with two rare kinds of epilepsy.
The CBD-based medicine was greenlighted in Europe also for the treatment of the same conditions – Lennox-Gastaut syndrome (LGS) or Dravet syndrome – in conjunction with clobazam.
.
.